NDAORALTABLET
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EQUAGESIC (aspirin; meprobamate) by PharmaIN is clinical pharmacology meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Approved for anxiety. First approved in 1960.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EQUAGESIC is an oral fixed-dose combination tablet containing aspirin and meprobamate, approved in 1960 for anxiety treatment. Meprobamate acts as a central nervous system depressant affecting the thalamus and limbic system, while aspirin provides nonnarcotic analgesia with antipyretic and anti-inflammatory properties. This combination targets patients requiring both anxiolytic and analgesic relief.
LOE Approaching
Product lifecycle is approaching loss of exclusivity with low competitive pressure (30/100), signaling a declining commercial footprint and reduced team investment.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Aspirin is a nonnarcotic analgesic with antipyretic and anti-inflammatory…
Indications (1)
Career Relevance
Working on EQUAGESIC offers limited career momentum due to its LOE-approaching lifecycle, zero linked open roles, and commoditized competitive position. Professionals assigned to this product typically focus on managed decline, generic transition, or transitional roles within the sponsor organization.
Worked on EQUAGESIC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.